Literature DB >> 9137844

Possible mechanisms of valproate in migraine prophylaxis.

F M Cutrer1, V Limmroth, M A Moskowitz.   

Abstract

Valproate has been shown to be an effective prophylactic treatment in migraine. Investigation of the mechanism of its antimigraine action is difficult due to the broad range of its biochemical effects and the complex nature of migraine pathophysiology. Valproate increases brain GABA levels and, in doing so, may suppress migraine-related events in the cortex, perivascular parasympathetics or trigeminal nucleus caudalis. There is experimental evidence that it suppresses neurogenic inflammation and directly attenuates nociceptive neurotransmission. In addition, valproate reportedly alters levels of excitatory and inhibitory neurotransmitters and exerts direct effects on neuronal membranes in vitro. Valproate's observed effect may ultimately result from a combination of actions at different loci.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137844     DOI: 10.1046/j.1468-2982.1997.1702093.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  19 in total

1.  GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 2.  Prophylactic migraine therapy: mechanisms and evidence.

Authors:  Nabih M Ramadan
Journal:  Curr Pain Headache Rep       Date:  2004-04

3.  A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.

Authors:  Elham Bidabadi; Mehryar Mashouf
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

Review 4.  Calcitonin gene-related peptide (CGRP): a new target for migraine.

Authors:  Andrew F Russo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

5.  Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes.

Authors:  A A Parsons; S Bingham; P Raval; S Read; M Thompson; N Upton
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Antiepileptic Drug Therapy in Migraine Headache.

Authors:  Steve D. Wheeler
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

Review 7.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

9.  Familial and sporadic hemiplegic migraine: diagnosis and treatment.

Authors:  Nadine Pelzer; Anine H Stam; Joost Haan; Michel D Ferrari; Gisela M Terwindt
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

10.  Prophylaxis of migraine.

Authors:  Ivan Garza; Jerry W Swanson
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.